MedTrace Logo

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

NCT03575078 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-09-25

No results posted yet for this study

Summary

Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of ARQ761 and a PARP inhibitor, Olaparib

Conditions

Interventions

DRUG

ARQ761, Olaparib

ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Muhammad Beg · UTexas Southwestern

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2019-05-15
Completion
2019-05-15
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03575078 on ClinicalTrials.gov